open access

Vol 52, No 1 (2014)
Original paper
Submitted: 2013-03-12
Accepted: 2014-03-28
Published online: 2014-05-07
Get Citation

Influence of infliximab pretreatment on ischemia/reperfusion injury in rat intestine

Remzi Adnan Akdogan, Yıldıray Kalkan, Levent Tumkaya, Hasan Alacam, Basar Erdivanli, Ibrahim Aydin
DOI: 10.5603/FHC.2014.0004
·
Folia Histochem Cytobiol 2014;52(1):36-41.

open access

Vol 52, No 1 (2014)
ORIGINAL PAPERS
Submitted: 2013-03-12
Accepted: 2014-03-28
Published online: 2014-05-07

Abstract

The Pringle maneuver is used in hepatic surgery to prevent blood loss but is associated with ischemia- reperfusion injury. To investigate the effect of infliximab on inflammation and apoptosis in rat intestinal mucosa during ischemia-reperfusion (IR) injury. A total of 30 male Wistar albino rats were equally divided into three groups to be subjected to (i) sham operation (sham), (ii) IR injury via Pringle maneuver (pringle) or (iii) infliximab (IFX) group (IFX was given at a dose 3 mg/kg for 3 days before IR injury). Following reperfusion period of 60 min., intestinal tissue and blood samples were taken and processed by standard histological methods. The Pringle maneuver and following reperfusion caused significant histopathological changes, increased serum transaminases’ activity and the levels of oxidative stress markers and decreased glutathione peroxidase activity. IFX pretreatment partially prevented these changes. Infliximab pretreatment may protect intestinal mucosa against ischemia-reperfusion injury. Further studies are needed to investigate mechanism and evaluate safety and optimal dosing of IFX in humans exposed to the possible tissue damage by ischemia-reperfusion. (Folia Histochemica et Cytobiologica 2014, Vol. 52, No. 1, 36–41)

Abstract

The Pringle maneuver is used in hepatic surgery to prevent blood loss but is associated with ischemia- reperfusion injury. To investigate the effect of infliximab on inflammation and apoptosis in rat intestinal mucosa during ischemia-reperfusion (IR) injury. A total of 30 male Wistar albino rats were equally divided into three groups to be subjected to (i) sham operation (sham), (ii) IR injury via Pringle maneuver (pringle) or (iii) infliximab (IFX) group (IFX was given at a dose 3 mg/kg for 3 days before IR injury). Following reperfusion period of 60 min., intestinal tissue and blood samples were taken and processed by standard histological methods. The Pringle maneuver and following reperfusion caused significant histopathological changes, increased serum transaminases’ activity and the levels of oxidative stress markers and decreased glutathione peroxidase activity. IFX pretreatment partially prevented these changes. Infliximab pretreatment may protect intestinal mucosa against ischemia-reperfusion injury. Further studies are needed to investigate mechanism and evaluate safety and optimal dosing of IFX in humans exposed to the possible tissue damage by ischemia-reperfusion. (Folia Histochemica et Cytobiologica 2014, Vol. 52, No. 1, 36–41)

Get Citation

Keywords

Pringle maneuver; ischemia-reperfusion injury; TNF; infliximab; calcineurin; caspase 3; transaminases; oxidative stress

About this article
Title

Influence of infliximab pretreatment on ischemia/reperfusion injury in rat intestine

Journal

Folia Histochemica et Cytobiologica

Issue

Vol 52, No 1 (2014)

Article type

Original paper

Pages

36-41

Published online

2014-05-07

DOI

10.5603/FHC.2014.0004

Bibliographic record

Folia Histochem Cytobiol 2014;52(1):36-41.

Keywords

Pringle maneuver
ischemia-reperfusion injury
TNF
infliximab
calcineurin
caspase 3
transaminases
oxidative stress

Authors

Remzi Adnan Akdogan
Yıldıray Kalkan
Levent Tumkaya
Hasan Alacam
Basar Erdivanli
Ibrahim Aydin

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl